# TRETHERA CORPORATION: Development of a Novel, Targeted Small Molecule Inhibitor of the Nucleoside Salvage Pathway to Treat Crohn's disease

**Lab Budget Score:** 55/100

| Field | Value |
|---|---|
| Organization | TRETHERA CORPORATION |
| Location | SHERMAN OAKS, CA |
| Project | Development of a Novel, Targeted Small Molecule Inhibitor of the Nucleoside Salvage Pathway to Treat Crohn's disease |
| Project number | 5R42DK138578-03 |
| Mechanism | R42 |
| Institute | National Institute of Diabetes and Digestive and Kidney Diseases |
| Award | $897,265 |
| Awarded | 2026-09-17 |
| Project period | 2023-09-18 to 2027-08-31 |
| UEI | QB66ZMAUF5P7 |

## Why this score
- Award of $400K or more.
- Research or center grant: supplies, instruments and services budget.

Source: NIH RePORTER (newly awarded projects) (https://reporter.nih.gov/project-details/11403971). Last refreshed: 2026-11-04T21:37:56.465Z.
Award data comes from NIH RePORTER and may be revised by NIH. Organization-level only; investigator names and contacts are not included. Informational only.